67593-46-8Relevant articles and documents
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists
Arhancet, Graciela B.,Woodard, Scott S.,Iyanar, Kaliappan,Case, Brenda L.,Woerndle, Rhonda,Dietz, Jessica D.,Garland, Danny J.,Collins, Joe T.,Payne, Maria A.,Blinn, James R.,Pomposiello, Silvia I.,Hu, Xiao,Heron, Marcia I.,Huang, Horng-Chih,Lee, Len F.
experimental part, p. 5970 - 5978 (2010/11/02)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.
Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
-
, (2008/06/13)
Benzylidene intermediates, useful in the preparation of dihydropyridines such as nifedipine and amlodipine, are formed by reaction of a ketocarboxylic adid ester with an aldehyde in the presence of a catalytic amount of dimethylamine acetate.